Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow BSX
Boston Scientific Corporation (BSX) EV/FCF
As of 16 October 2026, Boston Scientific Corporation (BSX) trades at a EV/FCF of 21.3×. Over the past ten years it has ranged from 20.2× (October 2026) to 7,898× (March 2019); the current reading is higher than 1% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 41.2× | (23.17%) |
| FY2024 | 53.6× | 4.08% |
| FY2023 | 51.5× | (33.73%) |
| FY2022 | 77.7× | 52.98% |
| FY2021 | 50.8× | (0.39%) |
| FY2020 | 51.0× | (3.08%) |
| FY2019 | 52.6× | (99.24%) |
| FY2018 | 6,964× | 19,142.91% |
| FY2017 | 36.2× | (13.64%) |
| FY2016 | 41.9× | (38.16%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 20.6× | (30.19%) |
| Mar 2026 | 29.6× | (28.19%) |
| Dec 2025 | 41.2× | 1.60% |
| Sep 2025 | 40.5× | (16.92%) |
| 42 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PHG Koninklijke Philips N.V. compare | 16.1× |
| BSX Boston Scientific Corporation | 21.3× |
| MDT Medtronic PLC compare | 22.9× |
| DXCM DexCom, Inc. compare | 23.5× |
| STE STERIS plc compare | 24.7× |
| GEHC GE HealthCare Technologies Inc. compare | 25.9× |
| SYK Stryker Corporation compare | 26.5× |
| ABT Abbott Laboratories compare | 26.8× |
| EW Edwards Lifesciences Corporation compare | 33.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on BSX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement